Publications

• Summary page
• Research Interest
• Publications
• Opportunities
• Funding

Preprint

1. Boikova A, Quaife-Ryan GA, Batho CAP, Lawrence E, Robinson H, Ascanelli C, Jennbacken K, Wang Q, Hansson KM, Seaton A, Rodriguez Noci V, Bywater M, Straube J, Sokolowski KA, Tse BWC, Krieg T, Vujic A, Porrello ER, Sinha S, Hudson JE, Wilson CH. (2023) A transient modified mRNA encoding Myc and Cyclin T1 induces cardiac regeneration and improves cardiac function after myocardial injury. https://biorxiv.org/cgi/content/short/2023.08.02.551469v1. In review in Circulation.
2. James P Higham, Charity N Bhebhe, Rohit A Gupta, Michael Tranter, Farah M Barakat, Harween Dogra, Natalie Bab, Eva Wozniak, Katie H Barker, Catherine H Wilson, Charles Mein, Tim Raine, James J Cox, John N Wood, Nicholas Croft, Paul Wright, David C Bulmer. (2023) Transcriptomic profiling reveals a pro-nociceptive role for Angiotensin II in inflammatory bowel disease. https://www.biorxiv.org/content/10.1101/2023.06.16.545265v1 In review in Pain.

Peer reviewed

1. Boikova A, Bywater MJ, Quaife-Ryan GA, Straube J, Thompson L, Ascanelli C, Littlewood TD, Evan GI, Hudson JE, Wilson CH. HRas and Myc synergistically induce cell-cycle progression and apoptosis of murine cardiomyocytes. (2022) Frontiers in Cardiovascular Medicine 9, 948281
2. Hall Z*, Wilson CH, Burkhart DL, Ashmore T, Evan GI, Griffin JL. Myc linked to dysregulation of cholesterol transport and storage in non-small cell lung cancer (2020). J Lipid Research 61(11):1390-1399.
3. Bywater MJ, Burkhart DL, Sabò A, Straube J, Pendino V, Hudson JE, Quaife-Ryan GA, Porrello ER, Rae J, Parton RG, Kress TR, Amati B, Littlewood TD, Evan GI*, Wilson CH*.  Reactivation of Myc transcription in the mouse heart unlocks its proliferative capacity (2020). Nat Comms 11(1):1827
4. Bywater, M. J. et al: ‘Reactivation of Myc transcription in the mouse heart unlocks its proliferative capacity.’ Nature Communications, April 2020. DOI: 10.1038/s41467-020-15552-x
5. Kreuzaler P*, Clarke M*, Brown E, Wilson CH, Piterman N, Littlewood TD, Evan GI, Fisher J. Heterogeneity of Myc Expression in Breast Cancer Reveals New Susceptibilities through Executable Mechanistic Modelling (2019). PNAS 116 (44), 22399-22408. https://doi.org/10.1073/pnas.1903485116.
6. Kortlever RM, Sodir NS, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, Littlewood TD, Evan GI. Myc cooperates with Ras by programming inflammation and immune suppression (2017). Cell 171(6):1301-1315.e14. https://doi.org/10.1016/j.cell.2017.11.01
7. Gamper I*, Burkhart DL*, Bywater MJ*, Garcia D*, Wilson CH, Kreuzaler PA, Arends MJ, Littlewood TD, Zheng Y, Perfetto A, Evan GI. Determination of the physiological and pathological roles of E2f3 in adult tissues (2017). Sci Rep 7(1):9932. https://doi.org/10.1038/s41598-017-09494-6
8. Hall Z, Ament Z*, Wilson CH*, Burkhart DL*, Koulman A, Littlewood TL, Evan GI, Griffin JL. Myc linked to aberrant lipid metabolism in lung cancer by mass spectrometry imaging (2016). Cancer Research 76(16):4608-18. * Joint second author. DOI: 10.1158/0008-5472.CAN-15-3403
9. Rashid M, Fischer A, Wilson CH, Tiffen J, Rust AG, Stevens P, Mustonen V, Williamns G, Sampson J, David J. Adams Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: Somatic landscape and driver genes (2015). Journal of Pathology 238(1):98-108. https://doi.org/10.1002/path.4643
10. Wilson CH, Gamper I, Perfetto A, Auw J, Littlewood TD, Evan GI (2013) The kinetics of ER fusion protein activation in vivo. Oncogene 33(40):4877-80. https://doi.org/10.1038/onc.2014.78
11. Kerr JS and Wilson CH (2013) Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase. Biochem Soc Trans 40;4:1055-1060. https://doi.org/10.1042/BST20130069
12. Wilson CH, Crombie C, van der Weyden L, Poulogiannis G, Rust AG , Pardo M, Gracia T, Yu L, Choudhary J, Poulin GB, McIntyre RE, Winton D, March NH, Arends MJ, Fraser AG, Adams DJ (2012) Nuclear Receptor Binding Protein 1 (NRBP1) regulates intestinal progenitor cell homeostasis and tumor formation. EMBO J 31: 2486-2497. https://doi.org/10.1038/emboj.2012.91
13. Naguib A, Wilson CH, Adams DJ, Arends MJ. (2010) Activation of KRAS by co-mutation of codons 19 and 20 is transforming. Journal of molecular signaling. 3;6:2. https://doi.org/10.1186/1750-2187-6-2
14. Wilson CH*, McIntyre RE*, Arends MJ, Adams DJ (2010) The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice via activation of Wnt and ERK1/2 MAPK pathways. Oncogene. 12;29(32):4567-75. * Joint first author. https://doi.org/10.1038/onc.2010.202
15. Poulogiannis G, McIntyre R, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ. (2010) PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. PNAS. 107(34):15145-50. https://doi.org/10.1073/pnas.1009941107
16. Mattison J, Kool J, Uren A, de Ridder J, Wessels L, Jonkers J, Bignell G, Butler A, Rust A, Brosch M, Wilson CH, van der Weyden L, Largaespada D, Stratton M, Futreal A, van Lohuizen M,  Berns A, Collier L, Hubbard T, Adams DJ (2010) Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. Cancer Res. 1;70(3):883-95. DOI: 10.1158/0008-5472.CAN-09-1737
17. Idziaszczyk S, Wilson CH*, Smith CG, Adams DJ and Cheadle JP (2010) Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer. -Cancer Genetics and Cytogenetics. 202(1):67-9. * Corresponding author. https://doi.org/10.1016/j.cancergencyto.2010.04.023
18. Uren A, Mikkers H, Kool J, van der Weyden L, Lund A, Wilson CH, Rance R, Jonkers J, van Lohuizen M, Berns A, Adams DJ (2009) A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc. 4(5):789-98. https://doi.org/10.1038/nprot.2009.64
19. Wilson C, Bonnet C, Guy C, Idziaszczyk S, Colley J, Humphreys V, Maynard J, Sampson JR, Cheadle JP. (2006) Tsc1-haploinsufficiency without mTOR activation is sufficient for renal cyst formation in Tsc1+/- mice. Cancer Res. 15;66(16):7934-8.DOI: 10.1158/0008-5472.CAN-06-1740
20. Patel GK, Wilson CH, Harding KG, Finlay AY, Bowden PE. (2006). J Invest Dermatol. 126(2): 497-502. https://doi.org/10.1038/sj.jid.5700101
21. Wilson C, Idziaszczyk S, Colley J, Humphreys V, Guy C, Maynard J, Sampson JR, Cheadle JP. (2005) Induction of renal tumorigenesis with elevated levels of somatic loss of heterozygosity in Tsc1+/- mice on a Blm-deficient background. Cancer Res. 65(22): 10179-82. DOI: 10.1158/0008-5472.CAN-05-2688
22. Wilson C, Idziaszczyk S, Parry L, Guy C, Griffiths DF, Lazda E, Bayne RA, Smith AJ, Sampson JR, Cheadle JP. (2005) A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Hum Mol Genet. 14(13): 1839-50. https://doi.org/10.1093/hmg/ddi190